In 2006, RotaTeq®, a bovine-human reassortant rotavirus vaccine containing five different strains (RV5) was licensed by the Food and Drug Administration and recommended for routine use as a three-dose vaccine to be given at 2, 4 and 6 months of age. Two years later, in 2008, RotaRix®, an attenuated human rotavirus vaccine containing one strain (RV1), was licensed as a two-dose vaccine to be given at 2 and 4 months of age.

In May 2016, Margaret Cortese and colleagues at the Centers for Disease Control and Prevention (CDC) compared the short and longer-term efficacy of these two vaccines, now that they have been available for almost 10 years (Immergluck LC, et al. Sustained effectiveness of monovalent and pentavalent rotavirus vaccines in children. J Pediatrics. 2016 May;172:116-120). 

Researchers compared 98 rotavirus case subjects with 175 rotavirus negative controls in children who presented to one of three Atlanta hospitals. They found that vaccine effectiveness among children 8 to 23 months of age was 80 percent for RV5 and 84 percent for RV1. Vaccine effectiveness among children ≥ 2 years of age was 82 percent for RV1 and 87 percent for RV5. The authors concluded that the RV1 and RV5 series of vaccines “were both effective against moderate-to-severe rotavirus disease … and both vaccines demonstrated sustained protection beyond the first two years of life.” 

Materials in this section are updated as new information and vaccines become available. The Vaccine Education Center staff regularly reviews materials for accuracy.

You should not consider the information in this site to be specific, professional medical advice for your personal health or for your family's personal health. You should not use it to replace any relationship with a physician or other qualified healthcare professional. For medical concerns, including decisions about vaccinations, medications and other treatments, you should always consult your physician or, in serious cases, seek immediate assistance from emergency personnel.